CurrentBlue Cross Blue Shield - MassachusettsPolicy 600

Transpupillary Thermotherapy (TTT) for Choroidal Neovascularization

This medical policy governs coverage of transpupillary thermotherapy (TTT) for choroidal neovascularization (including CNV secondary to age-related macular degeneration and other choroidal vascular conditions) for Blue Cross Blue Shield - Massachusetts members.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyTranspupillary Thermotherapy (TTT) for Choroidal Neovascularization

Policy CodePolicy 600

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionObtain precertification/preauthorization when the procedure is performed inpatient; outpatient prior authorization requirements vary by product.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Investigationalcoverage stance

No specific CPTCPT coding

Annualreview cycle

Comparative trialsevidence

Coverage Determination

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Not covered - Investigational

Policy determination

Investigational stance: Transpupillary thermotherapy for choroidal neovascularization (including CNV secondary to AMD and other choroidal vascular conditions) is considered investigational and is not covered.

Evidence is limited: trials versus sham did not show benefit; trials versus photodynamic therapy (PDT) show similar outcomes but possibly increased adverse events with TTT; TTT has not been compared with anti‑VEGF (angiogenesis inhibitor) therapy, and evidence is insufficient to determine if TTT is as beneficial as established alternatives.

This policy applies to Blue Cross Blue Shield of Massachusetts members across commercial and Medicare product lines, including Managed Care (HMO and POS), Commercial PPO and Indemnity, Medicare HMO BlueSM, and Medicare PPO BlueSM. For services described in this policy, precertification/preauthorization is required when the procedure is performed inpatient; outpatient prior authorization requirements vary by product. The policy specifically addresses the use of transpupillary thermotherapy (TTT) for choroidal neovascularization (CNV) secondary to ocular conditions such as age-related macular degeneration.

Transpupillary thermotherapy (TTT) for choroidal neovascularization (including CNV secondary to age-related macular degeneration and other choroidal vascular conditions) is considered investigational and is not covered.

Provider Requirements and Actions

Prior Authorization

Prior Authorization Required

Precertification/prior authorization is required when the procedure is performed inpatient. For outpatient procedures, prior authorization requirements vary by product — check the member's contract and the payer's product rules to determine if outpatient precertification is required.

Precertification/prior authorization required for inpatient services for all products.
Outpatient prior authorization: may be required depending on product — verify member contract and product-specific rules.

Note

Alternative Therapy Considerations

When evaluating treatment options for choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD), consider established alternatives such as photodynamic therapy (PDT) and vascular endothelial growth factor (VEGF) antagonists (e.g., pegaptanib, ranibizumab, aflibercept). Bevacizumab is used off-label. PDT and anti-VEGF therapies may be used alone or in combination; comparative effectiveness and FDA approvals differ by agent.

Photodynamic therapy (PDT) — see related policy (Policy No. 9.03.08).
VEGF antagonists/angiostatics — pegaptanib (Macugen), ranibizumab (Lucentis), aflibercept (Eylea) (see Policy No. 9.03.24).
Bevacizumab (Avastin) — used off-label for AMD.
Laser photocoagulation — historically used but generally not appropriate for subfoveal lesions due to risk to central vision.

Billing Rule

Coding and Reporting

Providers must report services using the most current industry-standard procedure, revenue, and diagnosis codes, and include applicable modifiers. The inclusion of codes in policy materials is informational and does not guarantee coverage or payment; verify coverage according to the member's contract at time of service. Note: there is no specific CPT code for this procedure.

Report with up-to-date CPT/HCPCS/ICD-10 codes and modifiers where applicable.
Code lists in policy are informational only — coverage depends on member contract and benefit in effect at time of service.
No specific CPT code exists for this procedure.

Prior Authorization

Precertification and Coverage Status

Reiteration: prior authorization is required for inpatient procedures and may be required for outpatient procedures depending on product. Lack of required precertification may affect coverage. Always confirm prior authorization requirements before scheduling the service.

Failure to obtain required precertification/prior authorization may result in claim denial or reduced payment.
Confirm authorization requirements against the member's plan and obtain approval when required before performing the service.

Clinical Background

Choroidal neovascularization (CNV) is the pathologic growth of new choroidal blood vessels beneath the retina and is a common cause of adult-onset vision loss, most often associated with the exudative (wet) form of age-related macular degeneration. These abnormal vessels can leak fluid and blood, leading to scarring and irreversible central vision impairment.

Transpupillary thermotherapy (TTT) is a technique that delivers low-level heat through the pupil using a modified diode laser intended to gently heat subfoveal choroidal lesions while limiting damage to the overlying retinal pigment epithelium. Clinical evidence is limited: randomized trials versus sham have not demonstrated benefit, trials versus photodynamic therapy (PDT) show similar outcomes but may have higher adverse events with TTT, and TTT has not been adequately compared with angiogenesis (anti-VEGF) inhibitors. Because of these evidence limitations, TTT is considered investigational for CNV.

Definitions

Transpupillary thermotherapy (TTT) — definition and technique description

DefinitionTranspupillary thermotherapy (TTT) is a technique in which low-level heat is delivered through the pupil using a modified diode laser to gently heat subfoveal choroidal lesions while limiting damage to the overlying retinal pigment epithelium.

Intended effectHeat application to subfoveal choroidal lesions to induce therapeutic change while minimizing retinal pigment epithelium injury.

Delivery methodLow‑level thermal energy delivered transpupillarily via a modified diode laser.

Clinical role in CNVInvestigational therapy for choroidal neovascularization; evidence is insufficient to establish benefit compared with established treatments such as anti‑VEGF agents.

Policy implicationTTT is considered investigational for treatment of CNV and is not covered under this policy.

Choroidal neovascularization (CNV) — definition and clinical context

DefinitionChoroidal neovascularization (CNV) is the growth of new pathological choroidal blood vessels, commonly associated with the exudative (wet) form of age‑related macular degeneration (AMD).

Clinical significanceCNV is a major risk factor for severe, irreversible vision loss due to serous or hemorrhagic detachment of the retinal pigment epithelium and development of neovascular membranes.

Association with AMDOccurs in the wet (exudative/neovascular) form of AMD, which evolves more rapidly and is more vision‑threatening than the atrophic (dry) form.

Alternate termsAlso referred to as neovascular membranes or the neovascular (wet) form of AMD.

OpenPayer

Transpupillary Thermotherapy (TTT) for Choroidal Neovascularization

Coverage Determination

Coding and Billing Notes

Provider Requirements and Actions

Clinical Background

Definitions